Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gross Profit (2016 - 2025)

Historic Gross Profit for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q4 2025 value amounting to $53.4 million.

  • Vanda Pharmaceuticals' Gross Profit rose 551.04% to $53.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $203.1 million, marking a year-over-year increase of 832.35%. This contributed to the annual value of $203.1 million for FY2025, which is 832.35% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Gross Profit of $53.4 million as of Q4 2025, which was up 551.04% from $53.3 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Gross Profit registered a high of $63.3 million during Q3 2021, and its lowest value of $35.8 million during Q3 2023.
  • Moreover, its 5-year median value for Gross Profit was $53.3 million (2025), whereas its average is $52.1 million.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Gross Profit tumbled by 3940.13% in 2023 and then skyrocketed by 2614.68% in 2024.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' Gross Profit stood at $61.8 million in 2021, then dropped by 5.73% to $58.2 million in 2022, then decreased by 28.21% to $41.8 million in 2023, then grew by 21.01% to $50.6 million in 2024, then increased by 5.51% to $53.4 million in 2025.
  • Its Gross Profit was $53.4 million in Q4 2025, compared to $53.3 million in Q3 2025 and $49.9 million in Q2 2025.